Celgene Corporation’s EPS Will Double by 2020
Investors are watching Celgene Corporation (NASDAQ:CELG) closely on Monday after an article by Jack Hough on Barron’s said the New Jersey-based biotechnology company’s earnings per share are likely to more than double by 2020. The author considers that Celgene Corporation (NASDAQ:CELG) is spending heavily on Research and Development, albeit a decade of growth. The source said that the demand of Revlimid, Celgene Corporation’s drug for myeloma – a cancer that forms in plasma cells – is rising quickly. The company is spending billions on new drug development projects and research programs, and expects to receive the results of least 18 late-stage clinical trials by 2018.
With a stake containing around 3.77 million shares, Samuel Isaly’s OrbiMed Advisors is one of 64 funds from our database that hold long positions in Celgene Corporation (NASDAQ:CELG), as of the end of March.
Acquisition of Williams Companies: A Nuisance for Energy Transfer Equity
Energy Transfer Equity LP (NYSE:ETE) and Williams Companies Inc (NYSE:WMB) are set to face each other in Delaware Chancery court on Monday regarding a breach of agreement battle. According to The New York Times, Energy Transfer Equity LP (NYSE:ETE)’s bid to acquire Williams Companies Inc (NYSE:WMB) has become a debacle. The company is now trying to find a way out of this merger deal. The cost to drop the deal is around $2 billion. Energy Transfer expects the recent legal battle to end in the termination of the deal by the court.
Our data show that 31 hedge funds owned shares of Energy Transfer Equity LP (NYSE:ETE) at the end of the first quarter. Daniel S. Och’s OZ Management is notable among these shareholders, holding more than 8.92 million shares of the company. On the other hand, 52 funds were long Williams Companies Inc (NYSE:WMB). Keith Meister’s Corvex Capital owns 41.68 million shares of the company, according to its latest 13F filing.